Alexey Kozlenkov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alexey Kozlenkov has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Stella Dracheva
Friedman Brain Institute and Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, US
3 shared publications - Carlos Alejandro Toro
Spinal Cord Damage Research Center, Bronx, NY, United States
2 shared publications - Eran A. Mukamel
Department of Cognitive Science, University of California San Diego, La Jolla, US
2 shared publications - Junhao Li
Department of Cognitive Science, University of California San Diego, La Jolla, US
2 shared publications - Michael Wegner
Institut für Biochemie, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany
2 shared publications Ping Zhou
Research & Development James J. Peters VA Medical Center Bronx New York USA
2 shared publications
Latest Publications
- 16 October 2026
- Published by Wiley in Movement Disorders Clinical Practice
VPS13A Disease (Chorea‐Acanthocytosis) in Puerto Rico; New Genetic and Clinical Observations
Background: VPS13A disease is a very rare neurodegenerative disorder caused by mutations in the VPS13A gene. Its prevalence appears to be relatively high in Puerto Ricans, although limited genetic information has been available. Objectives: To describe the genetics of VPS13A disease (chorea‐acanthocytosis) in Puerto Rico. Methods: Data were obtained from Puerto Rican patients with genetically confirmed VPS13A disease. Results: Eighteen cases were identified, all carrying at least one of four mutations, c.1400_1401del, c.3556_3557dup, c.3889C>T, and c.2825‐253_2905‐374del (exon_27‐deletion); six additional single variants were detected. Seizures were the presenting symptom in 53% of patients. Conclusion: The presence of these probable founder mutations could explain the apparently increased prevalence in Puerto Rico; half of the described variants are newly described mutations and half have been previously reported. Enhanced clinical awareness of the spectrum of presenting symptoms and diagnostic clues, and improved access to genetic testing are essential for timely diagnosis in this population.
- 16 October 2026
- Published by Wiley in Movement Disorders Clinical Practice
VPS13A Disease (Chorea‐Acanthocytosis) in Puerto Rico; New Genetic and Clinical Observations
Background: VPS13A disease is a very rare neurodegenerative disorder caused by mutations in the VPS13A gene. Its prevalence appears to be relatively high in Puerto Ricans, although limited genetic information has been available. Objectives: To describe the genetics of VPS13A disease (chorea‐acanthocytosis) in Puerto Rico. Methods: Data were obtained from Puerto Rican patients with genetically confirmed VPS13A disease. Results: Eighteen cases were identified, all carrying at least one of four mutations, c.1400_1401del, c.3556_3557dup, c.3889C>T, and c.2825‐253_2905‐374del (exon_27‐deletion); six additional single variants were detected. Seizures were the presenting symptom in 53% of patients. Conclusion: The presence of these probable founder mutations could explain the apparently increased prevalence in Puerto Rico; half of the described variants are newly described mutations and half have been previously reported. Enhanced clinical awareness of the spectrum of presenting symptoms and diagnostic clues, and improved access to genetic testing are essential for timely diagnosis in this population.
- Open Access
- 15 October 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (10) , 2345
Boldine Attenuates Mechanical Allodynia and Mitigates Transcriptomic Changes in a Mouse Model of Chronic Constriction Injury
Background/Objectives: Neuropathic pain is a complex chronic disorder affecting roughly 7–10% of the population. Current neuropathic pain treatments fail to provide adequate relief in at least ~40% of patients and are usually accompanied by side effects that are sometimes severe. In this study, we investigated the effect of boldine, a natural occurring alkaloid, in attenuating peripheral nerve injury-induced neuropathic pain symptoms and transcriptomic changes. Methods: Male C57BL6 mice underwent chronic constriction injury (CCI) to the sciatic nerve. Customized diet containing boldine or control diet was administered immediately after surgery. Mechanical pain responses were measured by Von Frey filament test. Spontaneous pain-like weight bearing behavior was assessed using the dynamic weight bearing system. L3–L5 spinal cords were collected 15 days after injury and subjected to quantitative PCR and bulk RNA sequencing. Results: CCI led to ipsilateral hypersensitivity of mechanical pain responses and weight-bearing deficits including reduced rearing duration, ipsilateral/contralateral weight support ratio, and ipsilateral hind paw posed duration. Boldine treatment substantially attenuated CCI-induced mechanical allodynia but not the weight bearing deficits. Gene expression analysis showed that boldine inhibited CCI-induced upregulation of inflammatory mediators in the spinal cord. RNA sequencing analysis revealed several pain-related canonical pathways and upstream factors after CCI, and boldine treatment markedly reversed these CCI-induced transcriptomic changes. Conclusions: Early oral administration of boldine attenuated CCI-induced mechanical allodynia and was associated with reduced inflammatory gene expression and reversal of multiple injury-related transcriptomic changes in the spinal cord. These preliminary preclinical findings support further investigation of boldine and do not establish therapeutic efficacy in established neuropathic pain.
- 15 October 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (10) , 2345
Open AccessBoldine Attenuates Mechanical Allodynia and Mitigates Transcriptomic Changes in a Mouse Model of Chronic Constriction Injury
Background/Objectives: Neuropathic pain is a complex chronic disorder affecting roughly 7–10% of the population. Current neuropathic pain treatments fail to provide adequate relief in at least ~40% of patients and are usually accompanied by side effects that are sometimes severe. In this study, we investigated the effect of boldine, a natural occurring alkaloid, in attenuating peripheral nerve injury-induced neuropathic pain symptoms and transcriptomic changes. Methods: Male C57BL6 mice underwent chronic constriction injury (CCI) to the sciatic nerve. Customized diet containing boldine or control diet was administered immediately after surgery. Mechanical pain responses were measured by Von Frey filament test. Spontaneous pain-like weight bearing behavior was assessed using the dynamic weight bearing system. L3–L5 spinal cords were collected 15 days after injury and subjected to quantitative PCR and bulk RNA sequencing. Results: CCI led to ipsilateral hypersensitivity of mechanical pain responses and weight-bearing deficits including reduced rearing duration, ipsilateral/contralateral weight support ratio, and ipsilateral hind paw posed duration. Boldine treatment substantially attenuated CCI-induced mechanical allodynia but not the weight bearing deficits. Gene expression analysis showed that boldine inhibited CCI-induced upregulation of inflammatory mediators in the spinal cord. RNA sequencing analysis revealed several pain-related canonical pathways and upstream factors after CCI, and boldine treatment markedly reversed these CCI-induced transcriptomic changes. Conclusions: Early oral administration of boldine attenuated CCI-induced mechanical allodynia and was associated with reduced inflammatory gene expression and reversal of multiple injury-related transcriptomic changes in the spinal cord. These preliminary preclinical findings support further investigation of boldine and do not establish therapeutic efficacy in established neuropathic pain.
- Open Access
Epidural Thin Film Implants of Polymerized Curcumin Downregulate Inflammatory Markers and Improve Functional Recovery After Spinal Cord Injury in Mice
We demonstrate for the first time that the natural antioxidant curcumin, when copolymerized with PEG and sebacoyl chloride, results in biomaterials that are solution processable into free-standing, epidurally implantable thin films, in mice with spinal cord injury (SCI). We show that these novel products can be epidurally implanted at the lesion site following incomplete contusive spinal cord injury in mice. In the polymeric form, these materials quench reactive oxygen species on-contact and retain their activity for vastly extended timescales relative to the curcumin small molecule itself, which is potent but short lived. The epidural thin film biomaterial implant resulted in a statistically significant improvement in functional recovery after SCI. Mechanistically, myelin staining revealed that the polymerized curcumin materials greatly enhanced white matter sparing. Immunohistochemical analysis also showed that expression of GFAP and Ib1a are significantly downregulated 200 µm rostral (but not caudal) to the injury site. Finally, bulk RNA sequencing analysis showed greatly reduced activation of pro-inflammatory gene expression program. The primary conclusion from these experiments is that polymerized curcumin epidural thin films effectively improve outcomes following SCI. The benefits of these novel biomaterials are demonstrated in vivo , for the first time, and suggest that poly(pro-drug) thin film implants may provide safe chronic, local delivery of active drugs following SCI for extended timescales.
Open AccessEpidural Thin Film Implants of Polymerized Curcumin Downregulate Inflammatory Markers and Improve Functional Recovery After Spinal Cord Injury in Mice
We demonstrate for the first time that the natural antioxidant curcumin, when copolymerized with PEG and sebacoyl chloride, results in biomaterials that are solution processable into free-standing, epidurally implantable thin films, in mice with spinal cord injury (SCI). We show that these novel products can be epidurally implanted at the lesion site following incomplete contusive spinal cord injury in mice. In the polymeric form, these materials quench reactive oxygen species on-contact and retain their activity for vastly extended timescales relative to the curcumin small molecule itself, which is potent but short lived. The epidural thin film biomaterial implant resulted in a statistically significant improvement in functional recovery after SCI. Mechanistically, myelin staining revealed that the polymerized curcumin materials greatly enhanced white matter sparing. Immunohistochemical analysis also showed that expression of GFAP and Ib1a are significantly downregulated 200 µm rostral (but not caudal) to the injury site. Finally, bulk RNA sequencing analysis showed greatly reduced activation of pro-inflammatory gene expression program. The primary conclusion from these experiments is that polymerized curcumin epidural thin films effectively improve outcomes following SCI. The benefits of these novel biomaterials are demonstrated in vivo , for the first time, and suggest that poly(pro-drug) thin film implants may provide safe chronic, local delivery of active drugs following SCI for extended timescales.
Novel method of isolating nuclei of human oligodendrocyte precursor cells reveals substantial developmental changes in gene expression and H3K27ac histone modification
Oligodendrocyte precursor cells (OPCs) generate differentiated mature oligodendrocytes (MOs) during development. In adult brain, OPCs replenish MOs in adaptive plasticity, neurodegenerative disorders, and after trauma. The ability of OPCs to differentiate to MOs decreases with age and is compromised in disease. Here we explored the cell specific and age‐dependent differences in gene expression and H3K27ac histone mark in these two cell types. H3K27ac is indicative of active promoters and enhancers. We developed a novel flow‐cytometry‐based approach to isolate OPC and MO nuclei from human postmortem brain and profiled gene expression and H3K27ac in adult and infant OPCs and MOs genome‐wide. In adult brain, we detected extensive H3K27ac differences between the two cell types with high concordance between gene expression and epigenetic changes. Notably, the expression of genes that distinguish MOs from OPCs appears to be under a strong regulatory control by the H3K27ac modification in MOs but not in OPCs. Comparison of gene expression and H3K27ac between infants and adults uncovered numerous developmental changes in each cell type, which were linked to several biological processes, including cell proliferation and glutamate signaling. A striking example was a subset of histone genes that were highly active in infant samples but fully lost activity in adult brain. Our findings demonstrate a considerable rearrangement of the H3K27ac landscape that occurs during the differentiation of OPCs to MOs and during postnatal development of these cell types, which aligned with changes in gene expression. The uncovered regulatory changes justify further in‐depth epigenetic studies of OPCs and MOs in development and disease.
Novel method of isolating nuclei of human oligodendrocyte precursor cells reveals substantial developmental changes in gene expression and H3K27ac histone modification
Oligodendrocyte precursor cells (OPCs) generate differentiated mature oligodendrocytes (MOs) during development. In adult brain, OPCs replenish MOs in adaptive plasticity, neurodegenerative disorders, and after trauma. The ability of OPCs to differentiate to MOs decreases with age and is compromised in disease. Here we explored the cell specific and age‐dependent differences in gene expression and H3K27ac histone mark in these two cell types. H3K27ac is indicative of active promoters and enhancers. We developed a novel flow‐cytometry‐based approach to isolate OPC and MO nuclei from human postmortem brain and profiled gene expression and H3K27ac in adult and infant OPCs and MOs genome‐wide. In adult brain, we detected extensive H3K27ac differences between the two cell types with high concordance between gene expression and epigenetic changes. Notably, the expression of genes that distinguish MOs from OPCs appears to be under a strong regulatory control by the H3K27ac modification in MOs but not in OPCs. Comparison of gene expression and H3K27ac between infants and adults uncovered numerous developmental changes in each cell type, which were linked to several biological processes, including cell proliferation and glutamate signaling. A striking example was a subset of histone genes that were highly active in infant samples but fully lost activity in adult brain. Our findings demonstrate a considerable rearrangement of the H3K27ac landscape that occurs during the differentiation of OPCs to MOs and during postnatal development of these cell types, which aligned with changes in gene expression. The uncovered regulatory changes justify further in‐depth epigenetic studies of OPCs and MOs in development and disease.
- Open Access
Divergent impacts of C9orf72 repeat expansion on neurons and glia in ALS and FTD
Neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), are strongly influenced by inherited genetic variation, but environmental and epigenetic factors also play key roles in the course of these diseases. A hexanucleotide repeat expansion in the C9orf72 (C9) gene is the most common genetic cause of ALS and FTD. To determine the cellular alterations associated with the C9 repeat expansion, we performed single nucleus transcriptomics (snRNA-seq) and epigenomics (snATAC-seq) in postmortem samples of motor and frontal cortices from C9-ALS and C9-FTD donors. We found pervasive alterations of gene expression across multiple cortical cell types in C9-ALS, with the largest number of affected genes in astrocytes and excitatory neurons. Astrocytes increased expression of markers of activation and pathways associated with structural remodeling. Excitatory neurons in upper and deep layers increased expression of genes related to proteostasis, metabolism, and protein expression, and decreased expression of genes related to neuronal function. Epigenetic analyses revealed concordant changes in chromatin accessibility, histone modifications, and gene expression in specific cell types. C9-FTD patients had a distinct pattern of changes, including loss of neurons in frontal cortex and altered expression of thousands of genes in astrocytes and oligodendrocyte-lineage cells. Overall, these findings demonstrate a context-dependent molecular disruption in C9-ALS and C9-FTD, resulting in distinct effects across cell types, brain regions, and disease phenotypes. One Sentence Summary: C9orf72-associated ALS and FTD showed a distinct pattern of transcriptome changes, with the largest number of affected genes in C9-ALS in astrocytes and excitatory neurons in upper and deep layers.
Open AccessDivergent impacts of C9orf72 repeat expansion on neurons and glia in ALS and FTD
Neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), are strongly influenced by inherited genetic variation, but environmental and epigenetic factors also play key roles in the course of these diseases. A hexanucleotide repeat expansion in the C9orf72 (C9) gene is the most common genetic cause of ALS and FTD. To determine the cellular alterations associated with the C9 repeat expansion, we performed single nucleus transcriptomics (snRNA-seq) and epigenomics (snATAC-seq) in postmortem samples of motor and frontal cortices from C9-ALS and C9-FTD donors. We found pervasive alterations of gene expression across multiple cortical cell types in C9-ALS, with the largest number of affected genes in astrocytes and excitatory neurons. Astrocytes increased expression of markers of activation and pathways associated with structural remodeling. Excitatory neurons in upper and deep layers increased expression of genes related to proteostasis, metabolism, and protein expression, and decreased expression of genes related to neuronal function. Epigenetic analyses revealed concordant changes in chromatin accessibility, histone modifications, and gene expression in specific cell types. C9-FTD patients had a distinct pattern of changes, including loss of neurons in frontal cortex and altered expression of thousands of genes in astrocytes and oligodendrocyte-lineage cells. Overall, these findings demonstrate a context-dependent molecular disruption in C9-ALS and C9-FTD, resulting in distinct effects across cell types, brain regions, and disease phenotypes. One Sentence Summary: C9orf72-associated ALS and FTD showed a distinct pattern of transcriptome changes, with the largest number of affected genes in C9-ALS in astrocytes and excitatory neurons in upper and deep layers.
- Open Access
- 7 September 2018
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 4 (9) , eaau6190
A unique role for DNA (hydroxy)methylation in epigenetic regulation of human inhibitory neurons
DNA hydroxymethylation is a distinctive epigenetic regulator of human inhibitory neurons, potentially affecting brain diseases.
- 7 September 2018
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 4 (9) , eaau6190
Open AccessA unique role for DNA (hydroxy)methylation in epigenetic regulation of human inhibitory neurons
DNA hydroxymethylation is a distinctive epigenetic regulator of human inhibitory neurons, potentially affecting brain diseases.
- Open Access
DNA Methylation Profiling of Human Prefrontal Cortex Neurons in Heroin Users Shows Significant Difference between Genomic Contexts of Hyper- and Hypomethylation and a Younger Epigenetic Age
We employed Illumina 450 K Infinium microarrays to profile DNA methylation (DNAm) in neuronal nuclei separated by fluorescence-activated sorting from the postmortem orbitofrontal cortex (OFC) of heroin users who died from heroin overdose (N = 37), suicide completers (N = 22) with no evidence of heroin use and from control subjects who did not abuse illicit drugs and died of non-suicide causes (N = 28). We identified 1298 differentially methylated CpG sites (DMSs) between heroin users and controls, and 454 DMSs between suicide completers and controls (p < 0.001). DMSs and corresponding genes (DMGs) in heroin users showed significant differences in the preferential context of hyper and hypo DM. HyperDMSs were enriched in gene bodies and exons but depleted in promoters, whereas hypoDMSs were enriched in promoters and enhancers. In addition, hyperDMGs showed preference for genes expressed specifically by glutamatergic as opposed to GABAergic neurons and enrichment for axonogenesis- and synaptic-related gene ontology categories, whereas hypoDMGs were enriched for transcription factor activity- and gene expression regulation-related terms. Finally, we found that the DNAm-based “epigenetic age” of neurons from heroin users was younger than that in controls. Suicide-related results were more difficult to interpret. Collectively, these findings suggest that the observed DNAm differences could represent functionally significant marks of heroin-associated plasticity in the OFC.
Open AccessDNA Methylation Profiling of Human Prefrontal Cortex Neurons in Heroin Users Shows Significant Difference between Genomic Contexts of Hyper- and Hypomethylation and a Younger Epigenetic Age
We employed Illumina 450 K Infinium microarrays to profile DNA methylation (DNAm) in neuronal nuclei separated by fluorescence-activated sorting from the postmortem orbitofrontal cortex (OFC) of heroin users who died from heroin overdose (N = 37), suicide completers (N = 22) with no evidence of heroin use and from control subjects who did not abuse illicit drugs and died of non-suicide causes (N = 28). We identified 1298 differentially methylated CpG sites (DMSs) between heroin users and controls, and 454 DMSs between suicide completers and controls (p < 0.001). DMSs and corresponding genes (DMGs) in heroin users showed significant differences in the preferential context of hyper and hypo DM. HyperDMSs were enriched in gene bodies and exons but depleted in promoters, whereas hypoDMSs were enriched in promoters and enhancers. In addition, hyperDMGs showed preference for genes expressed specifically by glutamatergic as opposed to GABAergic neurons and enrichment for axonogenesis- and synaptic-related gene ontology categories, whereas hypoDMGs were enriched for transcription factor activity- and gene expression regulation-related terms. Finally, we found that the DNAm-based “epigenetic age” of neurons from heroin users was younger than that in controls. Suicide-related results were more difficult to interpret. Collectively, these findings suggest that the observed DNAm differences could represent functionally significant marks of heroin-associated plasticity in the OFC.